Converting HR Breast Cancer Into an Individualized Vaccine

Investigator: Jenny Chang, MD

Study Coordinator: Rabia Hashmani

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03804944

Phone: 346.238.5894

Protocol Number: PRO00024042

Description

Hormone receptor positive breast cancer HRBC is the most common cause of BC-related death. HRBC is characterized by a non-immunogenic microenvironment and consequently, modest responses have been observed with immune checkpoint blockade ICB alone or with chemotherapy in this subtype. While ICB therapy is likely to play an important role in the treatment of HR BC, combination strategies that overcome the innate lack of immunogenicity are needed.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials